علاج الساركوما الزليلية في المرضى الأصغر من 18 عامًا

References

DOI: 10.1016/j.esmoop.2023.101618

• The optimal approach to the treatment of SS in pediatric patients is now better defined.
• The disease is rare in the pediatric population, making it difficult to conduct randomized pediatric SS-specific clinical trials.
• In localized SS, this typically involves initial first-line resection, where feasible, plus adjuvant or second-line treatments, including a combination of full-dose doxorubicin and ifosfamide chemotherapy, depending on an individual risk stratification that takes account of tumor stage, site, and size.
• A prospective trial by the EpSSG in patients <21 years of age with nonmetastatic SS showed that with multimodal treatment, which included radiotherapy and a combination of doxorubicin and ifosfamide chemotherapy according to tumor stage, site, and size, 5-year EFS was 80.7% and OS was 90.7%.
• A joint analysis by the EpSSG and the Children's Oncology Group (COG), however, found that pediatric patients with a localized nonmetastatic SS tumor of grade 2 of any size or grades 3 and 5 cm that had been fully resected could be treated effectively with surgery alone.